QiHuangYiShen Granules Modulate the Expression of LncRNA MALAT1 and Attenuate Epithelial-Mesenchymal Transition in Kidney of Diabetic Nephropathy Rats

Background QiHuangYiShen granules (QHYS), a traditional Chinese herbal medicine formula, have been used in clinical practice for treating diabetic kidney disease for several years by our team. The efficacy of reducing proteinuria and delaying the decline of renal function of QHYS has been proved by our previous studies. However, the exact mechanism by which QHYS exerts its renoprotection remains largely unknown. Emerging evidence suggests that lncRNA MALAT1 is abnormally expressed in diabetic nephropathy (DN) and can attenuate renal fibrosis by modulating podocyte epithelial-mesenchymal transition (EMT). Objective In the present study, we aimed to explore whether QHYS could modulate lncRNA MALAT1 expression and attenuate the podocyte EMT as well as the potential mechanism related to the Wnt/β-catenin signal pathway. Methods SD rats were fed with the high-fat-high-sucrose diet for 8 weeks and thereafter administered with 30 mg/kg streptozotocin intraperitoneally to replicate the DN model. Quality control of QHYS was performed using high-performance liquid chromatography. QHYS were orally administered at 1.25, 2.5, and 5 g/kg doses, respectively, to the DN model rats for 12 weeks. Body weight, glycated haemoglobin, blood urea nitrogen, serum creatinine, 24-h proteinuria, and kidney index were measured. The morphologic pathology of the kidney was evaluated by Hematoxylin-eosin and Masson's trichrome staining. The expression level of lncRNA MALAT1 was determined by quantitative real-time polymerase chain reaction. In addition, the expression levels of podocyte EMT protein markers and Wnt/β-catenin pathway proteins in renal tissues were evaluated by Western blotting and immunohistochemistry. Results The results showed that QHYS significantly reduced 24-h proteinuria, blood urea nitrogen, kidney index, and ameliorated glomerular hypertrophy and collagen fiber deposition in the kidney of DN rats. Importantly, QHYS significantly downregulated the expression level of lncRNA MALAT1, upregulated the expression of nephrin, the podocyte marker protein, downregulated the expression of desmin and FSP-1, and mesenchymal cell markers. Furthermore, QHYS significantly downregulated the expression levels of Wnt1, β-catenin, and active β-catenin. Conclusion Conclusively, our study revealed that QHYS significantly reduced proteinuria, alleviated renal fibrosis, and attenuated the podocyte EMT in DN rats, which may be associated with the downregulation of lncRNA MALAT1 expression and inhibition of the Wnt/β-catenin pathway.

[1]  Guanchi Yan,et al.  The Impact of lncRNA on Diabetic Kidney Disease: Systematic Review and In Silico Analyses , 2022, Computational intelligence and neuroscience.

[2]  C. Maher,et al.  Long noncoding RNAs in cancer metastasis , 2021, Nature Reviews Cancer.

[3]  Zhenying Ge,et al.  lncRNA MALAT1 Promotes Renal Fibrosis in Diabetic Nephropathy by Targeting the miR-2355-3p/IL6ST Axis , 2021, Frontiers in Pharmacology.

[4]  A. Kourtidis,et al.  LNCcation: lncRNA localization and function , 2021, The Journal of cell biology.

[5]  Lingling Zhang,et al.  Tanshinone IIA Ameliorates Streptozotocin-Induced Diabetic Nephropathy, Partly by Attenuating PERK Pathway-Induced Fibrosis , 2020, Drug design, development and therapy.

[6]  Qingfeng Hu,et al.  LncRNA MALAT1/microRNA let-7f/KLF5 axis regulates podocyte injury in diabetic nephropathy. , 2020, Life sciences.

[7]  Lian-ji Zhou,et al.  Circulating Expression Level of LncRNA Malat1 in Diabetic Kidney Disease Patients and Its Clinical Significance , 2020, Journal of diabetes research.

[8]  Enyu Wang,et al.  Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy. , 2020, Pharmacological research.

[9]  Jianbo Wang,et al.  Panax Notoginseng Ameliorates Podocyte EMT by Targeting the Wnt/β-Catenin Signaling Pathway in STZ-Induced Diabetic Rats , 2020, Drug design, development and therapy.

[10]  N. Kawashita,et al.  High-fat diet and streptozotocin in the induction of type 2 diabetes mellitus: a new proposal. , 2019, Anais da Academia Brasileira de Ciencias.

[11]  V. Yang,et al.  Podocyte-Specific Loss of Krüppel-Like Factor 6 Increases Mitochondrial Injury in Diabetic Kidney Disease , 2018, Diabetes.

[12]  N. Zhang,et al.  Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice , 2018, Drug design, development and therapy.

[13]  Hongyan Chen,et al.  Astragaloside IV inhibits cell migration and viability of hepatocellular carcinoma cells via suppressing long noncoding RNA ATB. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[14]  Y. Kulkarni,et al.  Gallic acid attenuates type I diabetic nephropathy in rats. , 2018, Chemico-biological interactions.

[15]  S. Gui,et al.  Long noncoding RNA ENSRNOG00000037522 is involved in the podocyte epithelial-mesenchymal transition in diabetic rats , 2018, International journal of molecular medicine.

[16]  J. Mendell,et al.  Functional Classification and Experimental Dissection of Long Noncoding RNAs , 2018, Cell.

[17]  K. Tuttle,et al.  Diabetic Kidney Disease: Challenges, Progress, and Possibilities. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[18]  A. Ghasemi,et al.  A practical guide for induction of type-2 diabetes in rat: Incorporating a high-fat diet and streptozotocin. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[19]  A. Friedman,et al.  Diagnosis and Management of Type 2 Diabetic Kidney Disease. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[20]  Haoran Dai,et al.  Research Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy , 2017, Journal of diabetes research.

[21]  J. Zhen,et al.  LncRNA MALAT1 is dysregulated in diabetic nephropathy and involved in high glucose‐induced podocyte injury via its interplay with β‐catenin , 2017, Journal of cellular and molecular medicine.

[22]  Guan-zhong Wu,et al.  Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: an update , 2017, Renal failure.

[23]  Shuai Yang,et al.  Long Non-Coding RNA MALAT1 Mediates Transforming Growth Factor Beta1-Induced Epithelial-Mesenchymal Transition of Retinal Pigment Epithelial Cells , 2016, PloS one.

[24]  G. Wolf,et al.  Epithelial-to-Mesenchymal Transition in Diabetic Nephropathy: Fact or Fiction? , 2015, Cells.

[25]  Youhua Liu,et al.  Wnt/β-catenin signalling and podocyte dysfunction in proteinuric kidney disease , 2015, Nature Reviews Nephrology.

[26]  Vivienne Zhu,et al.  Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging , 2014, BMC Research Notes.

[27]  Lin Sun,et al.  A Glimpse of the Pathogenetic Mechanisms of Wnt/β-Catenin Signaling in Diabetic Nephropathy , 2013, BioMed research international.

[28]  D. Stolz,et al.  Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. , 2009, Journal of the American Society of Nephrology : JASN.

[29]  G. Tesch,et al.  Rodent models of streptozotocin‐induced diabetic nephropathy (Methods in Renal Research) , 2007, Nephrology.

[30]  S. Shankland,et al.  The podocyte's response to injury: role in proteinuria and glomerulosclerosis. , 2006, Kidney international.

[31]  R. Wiggins,et al.  Evaluation of a thick and thin section method for estimation of podocyte number, glomerular volume, and glomerular volume per podocyte in rat kidney with Wilms' tumor-1 protein used as a podocyte nuclear marker. , 2003, Journal of the American Society of Nephrology : JASN.

[32]  G. Reaven,et al.  A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. , 2000, Metabolism: clinical and experimental.